Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER+ HER2- locally-advanced or metastatic breast cancer. - Liang J; Ong C; Heslop K; Guan J; Kameswaran V; Daniel B; Shi M; Liang Y; Giltnane JM; Aimi J; Chang CW; Gates MR; et al. (Nature communications, 2026)